OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

Core Insights - OKYO Pharma Limited has received $1.9 million in non-dilutive funding to support the clinical development of urcosimod for treating neuropathic corneal pain (NCP), a condition with no FDA-approved therapies [1][2][3] Company Overview - OKYO Pharma is a clinical stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease, with its shares traded on NASDAQ [6] - The company aims to discover and develop novel molecules specifically targeting neuropathic corneal pain and dry eye disease [6] Product Development - Urcosimod, the lead drug candidate, is a lipid conjugated chemerin peptide agonist designed to treat ocular diseases by producing anti-inflammatory and pain-reducing effects [5] - Urcosimod has shown statistical significance in multiple endpoints in a completed Phase 2 trial for dry eye disease and has just completed a Phase 2 trial for neuropathic corneal pain [5][6] Market Need - Neuropathic corneal pain is a severe and underdiagnosed condition characterized by debilitating pain and sensitivity, currently treated off-label with no FDA-approved options available [4][5]